Loading
Life sciences · Journal article
Asian Journal of Oncology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hormone receptor-low (HR-low) breast cancer, defined by ASCO/CAP guidelines as displaying 1% to 10% estrogen and/or progesterone receptor expression, presents a significant clinical dilemma. Accounting for approximately 7% of cases, this cohort is characteristically associated with younger patients, high-grade tumors, elevated Ki-67 indices, and distinct biological heterogeneity. Clinically, HR-low tumors exhibit a profound paradox: while standard guidelines recommend managing them as luminal-type disease, their molecular features, high tumor-infiltrating lymphocyte counts, and PD-L1 expression profiles closely mirror basal-like, triple-negative breast cancer (TNBC). Pathological identification remains heavily confounded by subjective interpretation and preanalytical testing variations. Therapeutic outcomes further highlight this dual identity; HR-low tumors achieve high pathological complete response (pCR) rates to neoadjuvant chemotherapy and immunotherapy protocols (such as the KEYNOTE-522 regimen) that are comparable to TNBC, yet they experience worse overall survival than strongly HR-positive cancers. Conversely, large-scale data confirms a distinct overall survival benefit from adjuvant endocrine therapy, though extending this treatment beyond three years yields no additional survival advantage. Ongoing clinical uncertainty persists regarding their inclusion in major trials. Managing HR-low breast cancer requires transitioning away from rigid immunohistochemical thresholds toward a nuanced, personalized approach utilizing molecular profiling to accurately identify patient subsets most likely to benefit from targeted endocrine or immunotherapeutic strategies.